DEFEROXAMINE MESYLATE FOR INJECTION 2 G — DIN 02247022
DEFEROXAMINE MESYLATE : 2 G · PFIZER CANADA ULC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is DEFEROXAMINE MESYLATE FOR INJECTION?
DEFEROXAMINE MESYLATE FOR INJECTION 2 G contains DEFEROXAMINE MESYLATE : 2 G. It is listed in the Health Canada Drug Product Database under DIN 02247022, held by PFIZER CANADA ULC, supplied as POWDER FOR SOLUTION for INTRAPERITONEAL ; INTRAMUSCULAR ; SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 08-Aug-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEFEROXAMINE MESYLATE FOR INJECTION used for?
Deferoxamine Mesylate for Injection is indicated for: • Acute iron intoxication. • Chronic iron overload due to transfusion-dependent anemias. • Diagnosis of aluminum overload (deferoxamine infusion test). • Chronic aluminum overload in patients with End-Stage Renal Failure (ESRF) under maintenance dialysis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Deferoxamine cost around the world?
Deferoxamine is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Saudi Arabia | public | 3 | 3 | SAR███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
7 pack listings across 7 brand entries and 3 price bases, refreshed 05 Sep 2026. Ranges span every Deferoxamine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Deferoxamine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Deferoxamine, across 7 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 2 | 2 | DEFEROXAMINE MESYLATE FOR INJECTION | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 2 | 1 | DESFERAL 2G, DESFERAL 500MG | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 0 | PMS-DEFEROXAMINE | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | DEFEROXAMINE MESYLATE FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAPERITONEAL ; INTRAMUSCULAR ; SUBCUTANEOUS ; INTRAVENOUS |
| Pack configuration (monograph) | 500 mg deferoxamine mesylate /vial, 2 g deferoxamine mesylate /vial |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Deferoxamine |
|---|---|
| ATC code | V03AC01 |
| AHFS class | 64:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02247022 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2247022 |
| Brand name | DEFEROXAMINE MESYLATE FOR INJECTION |
| Generic / active ingredient | DEFEROXAMINE MESYLATE : 2 G |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | V03AC01 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V03AC |
| Current status | MARKETED |
| Status date | 08-Aug-2018 |
| Original market date | 2004-01-12 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administer parenterally (IV, IM, or SC). Max 6.0 g/24h. IV rate should not exceed 15 mg/kg/h. Dosage depends on severity of intoxication or overload.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to deferoxamine mesylate or any component of the container, except where desensitization is successful.
Warnings and precautions
Rapid IV injection (>15 mg/kg/h) can cause shock. Risk of hearing/visual disturbances. Risk of Yersinia infections and mucormycosis. Acute respiratory distress syndrome at excessive doses.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 7 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DEFEROXAMINE MESYLATE FOR INJECTION | 500 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02241600 |
| DESFERAL 500MG | 500 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 01981242 |
| DEFEROXAMINE MESYLATE FOR INJECTION | 2 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02261820 |
| DESFERAL 2G | 2 G | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 01981250 |
| PMS-DEFEROXAMINE | 500 MG | POWDER FOR SOLUTION | PHARMASCIENCE INC | CANCELLED POST MARKET | 02242055 |
| PMS-DEFEROXAMINE | 2 G | POWDER FOR SOLUTION | PHARMASCIENCE INC | CANCELLED POST MARKET | 02243450 |
2 · Same class — other molecules in ATC V03AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Deferasirox | APO-DEFERASIROX · APO-DEFERASIROX (TYPE J) · AURO-DEFERASIROX (TYPE J) · DEFERASIROX (TYPE J) · +11 more | 45 | 36 | Yes |
| Deferiprone | FERRIPROX · FERRIPROX MR · TARO-DEFERIPRONE | 5 | 5 | Yes |
| Deferoxamine | DEFEROXAMINE MESYLATE FOR INJECTION · DESFERAL 2G · DESFERAL 500MG · PMS-DEFEROXAMINE | 7 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V03AN | Carbon Dioxide · Combination · Helium · Medical Air · Medical Gases · +2 more | 112 | 43 |
| V03AB | Amyl Nitrite · Andexanet Alfa · Antidotes · Digitalis Antitoxin · Dimercaprol · +16 more | 87 | 31 |
| V03AE | Calcium Acetate · Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia · Lanthanum Carbonate · Patiromer Calcium · Polystyrene Sulphonate · +3 more | 40 | 19 |
| V03AF | Amifostine · Calcium Folinate · Dexrazoxane · Mesna · Palifermin · +1 more | 34 | 16 |
| V03AH | Diazoxide | 2 | 1 |
| V03AX | Cobicistat · Difelikefalin · Other Therapeutic Products | 8 | 1 |
| V03AZ | Ethanol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DEFEROXAMINE MESYLATE FOR INJECTION called?
The same molecule, Deferoxamine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DESFERAL | Latin | Morocco |
| FROXA | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.